NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2
Completed
- Conditions
- Noncontiguous Stage II Small Lymphocytic LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Small Lymphocytic Lymphoma
- Interventions
- Biological: apolizumabOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00089154
- Locations
- 🇺🇸
Chronic Lymphocytic Leukemia Research Consortium (CRC), La Jolla, California, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 3
Completed
- Conditions
- Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
- Interventions
- Biological: bevacizumabOther: placeboOther: laboratory biomarker analysisOther: pharmacogenomic studiesOther: pharmacological study
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 590
- Registration Number
- NCT00088894
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
Phase 2
Completed
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00089349
- Locations
- 🇺🇸
COG Phase I Consortium, Arcadia, California, United States
Cilengitide in Treating Patients With Acute Myeloid Leukemia
Phase 2
Terminated
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT00089388
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Phase 1
Terminated
- Conditions
- Hematopoietic/Lymphoid CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00089089
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1
Completed
- Conditions
- Male Breast CancerRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Basal Cell Carcinoma of the LipRecurrent Breast CancerRecurrent Colon CancerRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityRecurrent Gastric CancerRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityRecurrent Lymphoepithelioma of the NasopharynxRecurrent Lymphoepithelioma of the Oropharynx
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00089362
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Stage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00088959
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
Phase 1
Terminated
- Conditions
- B-cell Chronic Lymphocytic LeukemiaCutaneous B-cell Non-Hodgkin LymphomaAdult Grade III Lymphomatoid GranulomatosisRecurrent Grade 1 Follicular LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Marginal Zone LymphomaSmall Intestine Lymphoma
- Interventions
- Biological: ipilimumabOther: laboratory biomarker analysis
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00089076
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Phase 2
Completed
- Conditions
- DS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaDS Stage I Plasma Cell Myeloma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00088855
- Locations
- 🇺🇸
Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States
🇺🇸Danville Regional Medical Center, Danville, Virginia, United States
🇺🇸Frisbie Hospital, Rochester, New Hampshire, United States
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
Phase 2
Terminated
- Conditions
- Splenic Marginal Zone LymphomaContiguous Stage II Adult Diffuse Large Cell LymphomaTesticular LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaNoncontiguous Stage II Adult Diffuse Large Cell LymphomaStage I Adult Diffuse Large Cell LymphomaWaldenström Macroglobulinemia
- Interventions
- Biological: rituximabRadiation: indium In 111 ibritumomab tiuxetanRadiation: radiation therapyProcedure: positron emission tomography
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00088881
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States